News - Sprycel

Filter

Current filters:

Sprycel

Popular Filters

CML drug revenue in Japan to grow, despite global decline, says GlobalData

21-05-2013

Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

"NICE" news for Novartis CML drugs, but not for Bristol-Myers

22-03-2012

In final draft guidance issued this morning, UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Mixed NICE recommendations for CML and diabetes drugs

13-01-2012

In a batch of final guidances released this morning by the UK’s drug watchdog the Institute for…

Bristol-Myers SquibbBydureonDiabetesEli LillyEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

FDA warns of pulmonary arterial hypertension risk with Bristol-Myers’ Sprycel

13-10-2011

The US Food and Drug Administration is warning the public that drug major Bristol-Myers Squibb’s…

Bristol-Myers SquibbNorth AmericaOncologyPharmaceuticalRegulationSprycel

UK’s NICE says “no” to Novartis Tasigna and B-MS Sprycel, but better news on Afinitor

06-05-2011

The UK’s drug rationing body the National Institute for Health and Clinical Excellence (NICE) yesterday…

AfinitorBristol-Myers SquibbGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Back to top